股本结构
单位：万股
| 公告日期 | 2026-10-06 | 2026-08-04 | 2026-08-04 | 2026-06-26 | 2026-05-05 | 2026-05-05 |
|---|---|---|---|---|---|---|
| 证券总股本 | 9229.14 | 8817.38 | 8806.41 | 8793.65 | 8684.13 | 7883.99 |
| 普通股本 | 9229.14 | 8817.38 | 8806.41 | 8793.65 | 8684.13 | 7883.99 |
| 优先股 | 未披露 | 未披露 | 34.60 | 34.60 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-10-07 | 2026-07-28 | 2026-06-30 | 2026-06-24 | 2026-04-28 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-06 | 9229.14 | 未披露 |
更多>>
Common stock offered 4,117,648 shares by the company
|
2026-10-07 |
| 2026-08-04 | 8817.38 | 未披露 | 定期报告 | 2026-07-28 |
| 2026-08-04 | 8806.41 | 34.60 |
更多>>
From March 31, 2026 to June 30, 2026
Conversion of Series B Non-Voting Convertible Preferred Stock to common stock
Issuance of common stock in connection with follow-on offering, net of offering costs
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
|
2026-06-30 |
| 2026-06-26 | 8793.65 | 34.60 | 定期报告 | 2026-06-24 |
| 2026-05-05 | 8684.13 | 未披露 | 定期报告 | 2026-04-28 |
| 2026-04-16 | 8625.94 | 未披露 |
更多>>
1.Common Stock offered 6,500,000 shares by the company.
2.The underwriters exercised their option to purchase common stock 975,000 shares.
|
2026-04-16 |
| 2026-04-10 | 7878.44 | 未披露 | 定期报告 | 2026-04-02 |
| 2026-05-05 | 7883.99 | 36.27 |
更多>>
From December 31,2025 to March 31,2026
Issuance of common stock in connection with at-the-market offering program, net of financing costs
Issuance of common stock in connection with exercise of stock options
|
2026-03-31 |
| 2026-02-19 | 7854.02 | 36.27 | 定期报告 | 2026-02-12 |
| 2026-02-19 | 7818.98 | 36.27 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of common stock in connection with follow-on offering, net of financing costs
Issuance of common stock in connection with at-the-market offering program, net of financing costs
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
Vesting of restricted stock units
|
2025-12-31 |
| 2025-11-04 | 7759.21 | 未披露 | 定期报告 | 2025-10-29 |
| 2025-10-17 | 7746.75 | 未披露 | 定期报告 | 2025-10-15 |
| 2025-11-04 | 6047.18 | 36.27 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
Vesting of restricted stock units
|
2025-09-30 |
| 2025-08-05 | 6040.10 | 未披露 | 定期报告 | 2025-07-31 |
| 2025-08-05 | 6037.29 | 36.27 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
|
2025-06-30 |
| 2025-05-08 | 6035.36 | 未披露 | 定期报告 | 2025-05-02 |
| 2025-05-08 | 6027.56 | 36.27 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
|
2025-03-31 |
| 2025-02-27 | 6025.70 | 36.27 | 定期报告 | 2025-02-26 |
| 2025-02-27 | 6027.56 | 未披露 | 定期报告 | 2025-02-19 |
| 2025-02-27 | 6025.70 | 36.27 |
更多>>
From December 31, 2023 to December 31, 2024
Exchange of Series A non-voting convertible preferred stock for common stock
Conversion of Series B non-voting convertible preferred stock into common stock
Issuance of common stock in connection with at-the-market offering program, net of financing costs
Issuance of common stock in connection with follow-on offering, net of financing costs
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
Vesting of restricted stock units
|
2024-12-31 |
| 2024-11-19 | 5870.62 | 未披露 |
更多>>
Common Stock offered 7,275,000 shares by the company
|
2024-11-20 |
| 2024-11-07 | 5143.12 | 未披露 | 定期报告 | 2024-11-01 |
| 2024-11-07 | 5139.56 | 36.27 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with at-the-market offerings, net of offering costs
Vesting of restricted stock units
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
|
2024-09-30 |
| 2024-09-06 | 5091.97 | 36.27 | 定期报告 | 2024-09-05 |
| 2024-08-07 | 5079.24 | 未披露 | 定期报告 | 2024-08-01 |
| 2024-11-18 | 5078.34 | 36.27 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with exercise of pre-funded warrants
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock
Exchange of Series A non-voting convertible preferred stock for common stock
Conversion of Series B non-voting convertible preferred stock into common stock
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
|
2024-06-30 |
| 2024-05-30 | 5078.24 | 未披露 | 定期报告 | 2024-05-29 |
| 2024-05-09 | 4028.34 | 未披露 | 定期报告 | 2024-05-01 |
| 2024-04-19 | 3663.97 | 未披露 | 定期报告 | 2024-04-15 |
| 2024-11-18 | 3662.97 | 70.87 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
|
2024-03-31 |
| 2024-04-01 | 3660.48 | 未披露 | 定期报告 | 2024-03-19 |
| 2024-02-29 | 3615.09 | 未披露 | 定期报告 | 2024-02-21 |
| 2024-03-01 | 3614.90 | 未披露 | 定期报告 | 2024-02-15 |
| 2024-02-29 | 3605.71 | 58.70 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs
Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract
Conversion of Series A non-voting convertible preferred stock into common stock
Issuance of common stock in connection with private placement, net of financing costs
Issuance of common stock in connection with the asset acquisition of Spyre
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
|
2023-12-31 |
| 2023-12-22 | 3602.10 | 未披露 | 定期报告 | 2023-12-11 |
| 2023-11-15 | 404.89 | 108.63 | 定期报告 | 2023-11-09 |
| 2023-11-09 | 404.89 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-10-10 | 404.87 | 108.63 | 定期报告 | 2023-09-22 |
| 2023-09-07 | 404.77 | 未披露 |
更多>>
Aeglea BioTherapeutics, Inc. announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25.
|
2023-09-08 |
| 2023-08-11 | 10119.29 | 未披露 | 定期报告 | 2023-08-04 |
| 2023-08-07 | 9745.72 | 未披露 | 定期报告 | 2023-07-12 |
| 2023-05-11 | 6539.52 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock in connection with employee stock purchase plan
|
2023-03-31 |
| 2023-03-02 | 6539.52 | 未披露 | 定期报告 | 2023-02-21 |
| 2023-03-02 | 6535.03 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with employee stock purchase plan
|
2022-12-31 |
| 2022-11-03 | 6151.11 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of pre-funded warrants
|
2022-09-30 |
| 2022-08-04 | 6117.25 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs
Issuance of common stock in connection with exercise of pre-funded warrants
|
2022-06-30 |
| 2022-05-09 | 6117.25 | 未披露 |
更多>>
1.Common Stock Offered by 10,752,688 shares.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 49,419,873 shares of common stock outstanding as of March 31, 2022.
|
2022-05-09 |
| 2022-05-05 | 5041.98 | 未披露 | 定期报告 | 2022-04-28 |
| 2022-05-05 | 4941.99 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with employee stock purchase plan
|
2022-03-31 |
| 2022-03-08 | 4936.21 | 未披露 | 定期报告 | 2022-02-24 |
| 2022-03-08 | 4935.51 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with exercise of pre-funded warrants
|
2021-12-31 |
| 2021-11-04 | 4932.00 | 未披露 | 定期报告 | 2021-10-28 |
| 2021-11-04 | 4930.61 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
|
2021-09-30 |
| 2021-08-05 | 4906.46 | 未披露 | 定期报告 | 2021-07-30 |
| 2021-08-05 | 4902.60 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs
Issuance of common stock in connection with exercise of stock options
|
2021-06-30 |
| 2021-05-28 | 4902.43 | 未披露 | 定期报告 | 2021-05-25 |
| 2021-05-10 | 4902.36 | 未披露 | 定期报告 | 2021-05-05 |
| 2021-04-22 | 4902.05 | 未披露 | 定期报告 | 2021-04-13 |
| 2021-05-10 | 4901.99 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with exercise of pre-funded warrants
|
2021-03-31 |
| 2021-03-18 | 4801.59 | 未披露 | 定期报告 | 2021-03-12 |
| 2021-03-18 | 4795.91 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs
|
2020-12-31 |
| 2020-11-05 | 4793.71 | 未披露 | 定期报告 | 2020-11-02 |
| 2020-11-05 | 4469.20 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
|
2020-09-30 |
| 2020-08-10 | 4459.98 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs
Issuance of common stock in connection with exercise of stock options
|
2020-06-30 |
| 2020-05-07 | 4459.38 | 未披露 | 定期报告 | 2020-05-01 |
| 2020-05-07 | 2914.75 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
|
2020-03-31 |
| 2020-02-24 | 2908.52 | 未披露 | 定期报告 | 2020-02-20 |
| 2020-02-24 | 2908.44 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs
|
2019-12-31 |
| 2019-11-06 | 2898.55 | 未披露 | 定期报告 | 2019-11-01 |
| 2019-11-06 | 2892.32 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
|
2019-09-30 |
| 2019-08-06 | 2888.55 | 未披露 | 定期报告 | 2019-08-01 |
| 2019-08-06 | 2884.83 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Issuance of common stock in connection with exercise of stock options
|
2019-06-30 |
| 2019-05-07 | 2883.74 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with public and at-the-market offerings, net of offering costs
|
2019-03-31 |
| 2019-03-07 | 2881.99 | 未披露 | 定期报告 | 2019-03-01 |
| 2019-03-07 | 2414.01 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with public and at-the-market offerings, net of offering costs
|
2018-12-31 |
| 2018-11-08 | 2396.21 | 未披露 | 定期报告 | 2018-11-02 |
| 2018-11-08 | 2209.82 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-09-06 | 2208.16 | 未披露 | 定期报告 | 2018-08-23 |
| 2018-08-09 | 2199.50 | 未披露 | 定期报告 | 2018-08-03 |
| 2018-08-09 | 2190.82 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-08 | 2185.89 | 未披露 | 定期报告 | 2018-05-04 |
| 2018-05-08 | 1680.97 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-13 | 1671.63 | 未披露 | 定期报告 | 2018-03-08 |
| 2018-03-13 | 1667.02 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Conversion of preferred stock to common stock upon initial public offering
Issuance of common stock in connection with initial public offering, net of offering costs
Issuance of common stock in connection with employee stock purchase plan
|
2017-12-31 |
| 2017-11-07 | 1664.43 | 未披露 | 定期报告 | 2017-11-03 |
| 2017-11-07 | 1647.28 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-09 | 1645.23 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-09 | 1345.23 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-23 | 1345.23 | 未披露 | 定期报告 | 2017-03-23 |
| 2017-03-23 | 1343.08 | 未披露 |
更多>>
from December 31, 2015 to September 30, 2016
Conversion of preferred stock to common stock upon initial public offering
Issuance of common stock in connection with initial public offering, net of offering costs
Issuance of common stock in connection with employee stock purchase plan
|
2016-09-30 |
| 2016-08-09 | 1341.18 | 未披露 |
更多>>
On March 28, 2016, the Company effected a 10.5-to-1 reverse stock split of all outstanding shares of the Company’s capital stock, including its common stock and its convertible preferred stock.
|
2016-06-30 |
| 2016-05-19 | 1341.18 | 未披露 |
更多>>
The reverse stock split became effective on March 28, 2016 and the Company closed its IPO on April 12, 2016. In connection with the IPO, all of the Company’s outstanding convertible preferred stock was converted into an aggregate total of 7,172,496 shares of common stock immediately prior to the closing of the IPO.
|
2016-05-19 |
| 2016-04-07 | 1292.98 | 未披露 | 定期报告 | 2016-04-07 |
| 2016-05-19 | 75.73 | 717.25 |
更多>>
On March 28, 2016, the Company effected a 10.5-to-1 reverse stock split of all outstanding shares of the Company’s capital stock, including its common stock and its convertible preferred stock.
|
2016-03-31 |
| 2016-03-28 | 75.73 | 717.25 |
更多>>
On March 28, 2016, the Company effected a 10.5-to-1 reverse stock split of all outstanding shares of the Company’s capital stock, including its common stock and its convertible preferred stock.
|
2016-03-28 |
| 2016-03-14 | 795.21 | 7531.15 | 定期报告 | 2015-12-31 |
| 2015-11-05 | 790.40 | 7531.15 | 定期报告 | 2015-09-30 |
| 2015-06-16 | 790.40 | 7457.62 | 定期报告 | 2014-12-31 |
Common stock offered 4,117,648 shares by the company
From March 31, 2026 to June 30, 2026
Conversion of Series B Non-Voting Convertible Preferred Stock to common stock
Issuance of common stock in connection with follow-on offering, net of offering costs
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
1.Common Stock offered 6,500,000 shares by the company.
2.The underwriters exercised their option to purchase common stock 975,000 shares.
From December 31,2025 to March 31,2026
Issuance of common stock in connection with at-the-market offering program, net of financing costs
Issuance of common stock in connection with exercise of stock options
From December 31, 2024 to December 31, 2025
Issuance of common stock in connection with follow-on offering, net of financing costs
Issuance of common stock in connection with at-the-market offering program, net of financing costs
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
Vesting of restricted stock units
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
Vesting of restricted stock units
From March 31, 2025 to June 30, 2025
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
From December 31, 2023 to December 31, 2024
Exchange of Series A non-voting convertible preferred stock for common stock
Conversion of Series B non-voting convertible preferred stock into common stock
Issuance of common stock in connection with at-the-market offering program, net of financing costs
Issuance of common stock in connection with follow-on offering, net of financing costs
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
Vesting of restricted stock units
Common Stock offered 7,275,000 shares by the company
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with at-the-market offerings, net of offering costs
Vesting of restricted stock units
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with exercise of pre-funded warrants
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock
Exchange of Series A non-voting convertible preferred stock for common stock
Conversion of Series B non-voting convertible preferred stock into common stock
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
From December 31, 2022 to December 31, 2023
Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs
Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract
Conversion of Series A non-voting convertible preferred stock into common stock
Issuance of common stock in connection with private placement, net of financing costs
Issuance of common stock in connection with the asset acquisition of Spyre
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan
Aeglea BioTherapeutics, Inc. announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25.
From December 31, 2022 to March 31, 2023
Issuance of common stock in connection with employee stock purchase plan
From December 31, 2021 to December 31, 2022
Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with employee stock purchase plan
From June 30, 2022 to September 30, 2022
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of pre-funded warrants
From March 31, 2022 to June 30, 2022
Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs
Issuance of common stock in connection with exercise of pre-funded warrants
1.Common Stock Offered by 10,752,688 shares.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 49,419,873 shares of common stock outstanding as of March 31, 2022.
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with employee stock purchase plan
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with exercise of pre-funded warrants
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
From March 31, 2021 to June 30, 2021
Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs
Issuance of common stock in connection with exercise of stock options
From December 31, 2020 To March 31, 2021
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with exercise of pre-funded warrants
from December 31, 2019 to December 31, 2020
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs
From June 30, 2020 to September 30, 2020
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
From March 31, 2020 to June 30, 2020
Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs
Issuance of common stock in connection with exercise of stock options
From December 31, 2019 to March 31, 2020
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
from December 31, 2018 to December 31, 2019
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs
from June 30, 2019 to September 30, 2019
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
from March 31, 2019 to June 30, 2019
Issuance of common stock in connection with exercise of stock options
from December 31, 2018 to March 31, 2019
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with public and at-the-market offerings, net of offering costs
from December 31, 2017 to December 31, 2018
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with exercise of stock options
Issuance of common stock in connection with public and at-the-market offerings, net of offering costs
from December 31, 2016 to December 31, 2017
Conversion of preferred stock to common stock upon initial public offering
Issuance of common stock in connection with initial public offering, net of offering costs
Issuance of common stock in connection with employee stock purchase plan
from December 31, 2015 to September 30, 2016
Conversion of preferred stock to common stock upon initial public offering
Issuance of common stock in connection with initial public offering, net of offering costs
Issuance of common stock in connection with employee stock purchase plan
On March 28, 2016, the Company effected a 10.5-to-1 reverse stock split of all outstanding shares of the Company’s capital stock, including its common stock and its convertible preferred stock.
The reverse stock split became effective on March 28, 2016 and the Company closed its IPO on April 12, 2016. In connection with the IPO, all of the Company’s outstanding convertible preferred stock was converted into an aggregate total of 7,172,496 shares of common stock immediately prior to the closing of the IPO.
On March 28, 2016, the Company effected a 10.5-to-1 reverse stock split of all outstanding shares of the Company’s capital stock, including its common stock and its convertible preferred stock.
On March 28, 2016, the Company effected a 10.5-to-1 reverse stock split of all outstanding shares of the Company’s capital stock, including its common stock and its convertible preferred stock.